Registration Options

Activity Dates: 04/25/2022 - 04/25/2025

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

Transgender individuals often experience discrimination, poverty, social stigmatization and marginalization, contributing to psychiatric illnesses such as anxiety disorders, major depression, and substance use disorders. Some transgender individuals experience distress or discomfort related to the difference in their assigned sex at birth and their gender identity and reach the threshold for a DSM-5 diagnosis of Gender Dysphoria. The symptoms of gender dysphoria can lead to functional consequences interfering with daily activities and may be associated with high levels of stigmatization, discrimination, incarceration, victimization, school dropout, unemployment, and increased rates of psychiatric comorbidities.

Given the substantially higher rates of suicide and psychiatric distress present in this population of patients (particularly when they are untreated or undertreated), it is imperative the mental health profession continues to identify and address the barriers persons with Gender Dysphoria face when seeking mental health treatment. Psychiatric pharmacists are in a key position to provide optimal mental health care to transgender persons with gender dysphoria as this population of patients will be encountered despite the area of specialization. This session is designed to provide education on treatment considerations for psychiatric comorbidities and psychiatric and medical side effects of gender affirming hormonal treatments in transgender patients.

Course Requirements

To receive ACPE credit for this session, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information

George Brown, MD, DFAPA

View biographical information

Learning Objectives

  1. Assess the effects of gender affirming hormonal treatments on mental and physical health of transgender patients.
  2. Evaluate the risks of psychiatric and medical adverse effects in transgender patients receiving gender affirming hormonal treatments.
  3. Formulate a treatment plan for transgender patients receiving gender affirming hormonal treatments.

Continuing Education Credit and Disclosures

Activity Dates: 04/25/2022 - 04/25/2025
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-042-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.